Table 1.
Median (range) | No. of patients | No. of CRPC | Median progression time (months) | No. of deaths | Median survival time (months) | ||||
---|---|---|---|---|---|---|---|---|---|
Total |
|
|
286 |
207 |
19 |
|
102 |
113 |
|
Age |
|
73 (50–91) |
|
|
|
|
|
|
|
|
≤75 |
|
179 |
132 |
19 |
|
69 |
85 |
|
|
≥76 |
|
107 |
75 |
18 |
n.s. |
33 |
none |
n.s. |
T |
T1 |
|
4 |
2 |
57 |
*(T2 vs. T3, T4) |
0 |
all alive |
|
|
T2 |
|
31 |
18 |
37 |
9 |
111 |
|
|
|
T3 |
|
162 |
114 |
19 |
60 |
83 |
|
|
|
T4 |
|
89 |
73 |
14 |
33 |
77 |
n.s. |
|
N |
N0 |
|
164 |
116 |
19 |
|
59 |
79 |
|
|
N1 |
|
122 |
91 |
19 |
n.s. |
43 |
99 |
n.s. |
M |
M0 |
|
50 |
31 |
26 |
|
9 |
99 |
|
|
M1 |
|
236 |
176 |
18 |
n.s. |
93 |
83 |
n.s. |
Gleason score |
6-8 |
|
181 |
83 |
21 |
* |
63 |
115 |
|
|
9-10 |
|
105 |
124 |
14 |
39 |
85 |
n.s. |
|
PSA at diagnosis |
|
174 (5.7-21864) |
|
|
|
|
|
|
|
|
<100 |
|
105 |
64 |
23 |
*(<100 vs. ≥500) |
31 |
85 |
|
|
100-500 |
|
97 |
73 |
16 |
36 |
113 |
|
|
|
≥500 |
|
84 |
70 |
15 |
35 |
none |
n.s. |
|
Nadir PSA level |
|
0.3 (0.001-650) |
|
|
|
|
|
|
|
|
<0.2 |
|
122 |
71 |
38 |
** |
26 |
115 |
*** |
|
0.2-4 |
|
112 |
86 |
13 |
44 |
62 |
||
|
≥4 |
|
52 |
50 |
8 |
32 |
25 |
||
Time from PADT to Nadir |
|
9.45 (1–64) |
|
|
|
|
|
|
|
|
≥12 |
|
114 |
74 |
35 |
** |
23 |
113 |
*** |
|
6-12 |
|
83 |
62 |
13 |
39 |
79 |
||
|
<6 |
|
89 |
71 |
7 |
40 |
28 |
||
Time from PADT to CRPC |
|
13 (1–97) |
|
|
|
|
|
|
|
|
No CRPC |
|
79 |
|
|
|
14 |
none |
|
|
≥12 |
|
112 |
|
|
|
32 |
113 |
*** |
|
6-12 |
|
63 |
|
|
|
34 |
35 |
|
<6 | 32 | 22 | 21 |
*P<0.005, **all P<0.001, ***P<0.001 without No CRPC vs. ≥12
PADT: primary androgen deprivation therapy.
CRPC: castration resistant prostate cancer.